Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q15375
UPID:
EPHA7_HUMAN
Alternative names:
EPH homology kinase 3; EPH-like kinase 11
Alternative UPACC:
Q15375; A0AUX7; B2R8W1; B7ZLJ9; B7ZLK0; Q59G40; Q5VTU0; Q8N368; Q9H124
Background:
Ephrin type-A receptor 7, also known as EPH homology kinase 3 or EPH-like kinase 11, is a pivotal receptor tyrosine kinase. It engages in bidirectional signaling via GPI-anchored ephrin-A family ligands, crucial for brain development, axon guidance, and topographic mapping of retinal axons. Its interaction with EFNA5 modulates cell-cell adhesion and repulsion, influencing corticothalamic axons' guidance and the colliculus's mapping.
Therapeutic significance:
Understanding the role of Ephrin type-A receptor 7 could open doors to potential therapeutic strategies.